IBEX Announces Departure of its Director of Finance

IBEX Technologies Inc. (TSX VENTURE:IBT) today announces the departure of Nancy
Bisson as Director of Finance.


Nancy left IBEX in order to pursue a new venture. IBEX would like to thank her
for her work with IBEX in the last five years and wishes her good luck in her
new career.


Effective immediately, and until the appointment of a new Director of Finance,
Paul Baehr, President and CEO will act as interim Director of Finance, in
addition to his current duties.


ABOUT IBEX

The Company, through its wholly owned subsidiaries, IBEX Pharmaceuticals Inc.
(Montreal) and Bio- Research Products Inc. (North Liberty, IA), manufactures and
markets a series of proprietary enzymes for use in diagnostic tests and
research. IBEX also manufactures and markets a series of arthritis assays which
are widely used in osteoarthritis research.


For more information, please visit the Company's website at www.ibex.ca.

The TSX Venture Exchange does not accept responsibility for the adequacy or
accuracy of this release.


Safe Harbor Statement

All of the statements contained in this news release, other than statements of
fact that are independently verifiable at the date hereof, are forward-looking
statements. Such statements, based as they are on the current expectations of
management, inherently involve numerous risks and uncertainties, known and
unknown. Some examples of known risks are: the impact of general economic
conditions, general conditions in the pharmaceutical industry, changes in the
regulatory environment in the jurisdictions in which IBEX does business, stock
market volatility, fluctuations in costs, and changes to the competitive
environment due to consolidation or otherwise. Consequently, actual future
results may differ materially from the anticipated results expressed in the
forward-looking statements. IBEX disclaims any intention or obligation to update
these statements.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Paul Baehr
President & CEO
IBEX Technologies Inc.
514-344-4004 x 143

Ibex Technologies (TSXV:IBT)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024